Epicardial Cardiac Fat-CT (EPIC-CT) (NCT07297589)
Epicardial Cardiac Fat Comparative Trial
🩺 Plain-English Summary (8th-Grade Level)
Both globally and nationally, heart disease remains the leading cause of death overall and across genders, with ischemic heart disease being the primary cause. It is now understood that multiple risk factors contribute to the development of this condition, notably type 2 diabetes mellitus and obesity, especially an increase in visceral fat. Among these, the role of epicardial fat volume in the presence of atheromatous plaques in patients with coronary artery disease has been emphasized, along with the link between its volume and the risk of ischemic cardiovascular events. Consequently, recent decades have seen focused research on the potential of epicardial fat as a marker for major adverse cardiac events and on strategies to reduce its volume as a treatment goal for patients with risk factors. Selective sodium-glucose cotransporter 2 inhibitors are drugs that, beyond their antihyperglycemic effect, have demonstrated cardiovascular benefits through various mechanisms, including a reduction in epicardial fat. This was supported by a previous study conducted by our research group, although no statistically significant difference was found. On the other hand, GLP-1 agonists are effective drugs for weight control in patients with severe obesity. However, little research has been done on their effect on more localized fat, such as epicardial fat.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (11 items).
Location: Unidad Medica de Alta Especialidad No. 1, Bajío — León, Guanajuato
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Patients who have recently received immunosuppressive therapy
- Patients with a history of ischemic heart disease
- Known allergy to any of the medications used
- Use of any of the study drugs more than 6 months prior to randomization
- Patients experiencing diabetic ketoacidosis
- Patients with hemodynamic instability (mean arterial pressure \<60 mmHg while on vasopressors)
- Pregnant women
- Patients with a history or current diagnosis of cancer
- Patients with documented active infections, such as pneumonia or urinary tract infections
- Patients with pancreatitis
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Unidad Medica de Alta Especialidad No. 1, Bajío — León, Guanajuato
📞 Contact the Study Coordinator
Phone: (477) 717-4800
Email: hildamacer@gmail.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in STEMI - ST Elevation Myocardial Infarction
- SuperSaturated Oxygen Comprehensive Observational Registry — Fountain Valley, California
Explore by condition: All STEMI - ST Elevation Myocardial Infarction clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.